scholarly journals Antithrombotic therapy in very elderly patients with atrial fibrillation: Is it enough to assess thromboembolic risk?

2010 ◽  
pp. 157 ◽  
Author(s):  
Yutao Guo
Keyword(s):  
Atrial Fibrillation ◽  
Elderly Patients ◽  
Antithrombotic Therapy ◽  
Very Elderly ◽  
Thromboembolic Risk

scholarly journals ASPECTS OF MULTICOMPONENT THERAPY AND PERIOPERATIVE TACTICS IN A PATIENT WITH ATRIAL FIBRILLATION RECEIVING RIVAROXABAN THERAPY. CLINICAL OBSERVATION

2019 ◽  
pp. 62-71
Author(s):  
O. A. Zemlyanskaya ◽  
E. S. Kropacheva
Keyword(s):  
Atrial Fibrillation ◽  
Catheter Ablation ◽  
Life Expectancy ◽  
Antithrombotic Therapy ◽  
Clinical Observation ◽  
Oral Anticoagulants ◽  
Point Of View ◽  
Systemic Embolism ◽  
Thromboembolic Risk ◽  
Practical Point

The use of modern oral anticoagulants is associated with a significant reduction in the risk of stroke and systemic embolism in patients with atrial fibrillation, and thus with an increase in the life expectancy of patients. That is why multicomponent therapy and perioperative tactics are actual during prolonged anticoagulation, the aspects of which seem to be one of the most difficult from the practical point of view. This clinical observation is an illustration of the management of a patient with atrial fibrillation at high thromboembolic risk who is receiving Rivaroxaban therapy and who has indications for catheter ablation and multicomponent antithrombotic therapy.

O4.03: Dabigatran etexilate and rivaroxaban show different safety and efficacy profile in very elderly patients with non valvular atrial fibrillation

2014 ◽  
Vol 5 ◽  
pp. S72 ◽  
Author(s):  
A.R. Gomez Quintanilla ◽  
E. Paredes Galan ◽  
A. Guitian Gonzalez ◽  
A. Vilches Moraga ◽  
C. Rodriguez Pascual
Keyword(s):  
Atrial Fibrillation ◽  
Elderly Patients ◽  
Dabigatran Etexilate ◽  
Very Elderly ◽  
Safety And Efficacy ◽  
Efficacy Profile
Sign in / Sign up

Export Citation Format

Share Document